Arix Bioscience plc

Arix Bioscience plc discloses dealings in 3 companies, chiefly LogicBio Therapeutics, Inc., Harpoon Therapeutics, Inc. and Enliven Therapeutics, Inc. In total, 25 filings cover trades dated from 23 October 2018 to 28 September 2020.

In open-market terms, that means 3 purchases worth €14.1M on one side and 19 sales worth €16.4M on the other. Netting one side against the other leaves €2.2M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2020 alone, the filings show 1 purchase and 12 sales.

Half of the purchases are above €5.3M and half below. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The latest filing, published on 5 October 2020, reports an open-market sale of €123k in LogicBio Therapeutics, Inc. The most recent open-market purchase was published on 16 March 2020, 2,412 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.